# AZAHAR Study To Describe Anifrolumab in a Real-World Setting

> **NCT06626945** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 152 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06626945
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-03
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-06-05
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626945, "AZAHAR Study To Describe Anifrolumab in a Real-World Setting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06626945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*